C=x Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding (x Is Chalcogen) Patents (Class 514/423)
-
Patent number: 8871798Abstract: This disclosure relates to compounds of formula I: wherein R1, R2, R3, R4, X and Y have the meanings denoted in the disclosure. The compounds of formula I have antithrombotic activity and in particular inhibit the protease-activated receptor 1 (PAR1). The disclosure further relates to a method for producing the compound of formula I and to the use thereof as a pharmaceutical product.Type: GrantFiled: October 16, 2012Date of Patent: October 28, 2014Assignee: SanofiInventors: Karl Schoenafinger, Henning Steinhagen, Bodo Scheiper, Uwe Heinelt, Volkmar Herrmann, Matthias Herrmann
-
Publication number: 20140314844Abstract: The present invention relates to an oral complex formulation comprising omega-3 fatty acid or its derivatives encapsulated in a hard or soft capsule containing sorbitol and sorbitan, as well as an HMG-CoA reductase inhibitor. The formulation of the present invention comprising omega-3 fatty acid encapsulated with sorbitol and sorbitan provides better prevention related materials from being formed, leading to improved long-term storage stability. The oral complex formulation of the present invention also can raise the serum HDL-cholesterol level, while reducing both LDL-cholesterol and TG levels. The oral complex formulation of the present invention is useful for treatment of hyperlipidemia.Type: ApplicationFiled: November 16, 2012Publication date: October 23, 2014Applicant: HANMI PHARM. CO., LTDInventors: Jin Cheul Kim, Jae Ho Kim, Eun Jin Yoon, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
-
Publication number: 20140315808Abstract: A method of treating a disease or condition in which up-regulating GAGs is therapeutically beneficial is disclosed. The method comprises locally administering to a subject a therapeutically effective amount of an agent capable of down-regulating activity or expression of a component of the renin-angiotensin system.Type: ApplicationFiled: June 30, 2014Publication date: October 23, 2014Inventors: Talia WEINSTEIN, Uzi GAFTER, Zvi NEVO, Dror ROBINSON, Zoharia EVRON
-
Publication number: 20140315805Abstract: Methods of improving recovery of a mammal after an ischemic event (e.g., stroke) are provided. In various embodiments the methods involve administering a neural growth factor (e.g., BDNF) into the infarct (e.g., stroke) cavity in a biocompatible hydrogel formulation. In certain embodiments the hydrogel comprises a thiolated hyaluronan and a thiolated gelatin with an optional thiolated heparin.Type: ApplicationFiled: March 1, 2012Publication date: October 23, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Stanley T. Carmichael, Andrew N. Clarkson
-
Publication number: 20140309273Abstract: Provided are new fatty acid derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, e.g., as agents for the treatment of obesity and related disorders, and for improving cognition.Type: ApplicationFiled: June 25, 2014Publication date: October 16, 2014Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., AL-QUDS UNIVERSITYInventors: Jehoshua KATZHENDLER, Meir SAIDIAN, Yousef NAJAJREH, Raphael MEVORACH, Elliot BERRY, Yosefa AVRAHAM
-
Publication number: 20140309190Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.Type: ApplicationFiled: June 17, 2014Publication date: October 16, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Ma Bin, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
-
Publication number: 20140308244Abstract: Provided herein include combination therapies for the treatment of neurological inflammatory diseases, such as, for example, demyelinating autoimmune diseases, such as multiple sclerosis and neuromyelitis optica, etc. In various aspects and embodiments, the methods may include administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ACE) in combination with one or more second compounds, In one aspect, provided is a method of treating a demyelinating autoimmune disease (such as multiple sclerosis) that includes administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ACE) in combination with one or more compounds selected from the group consisting of a cytokine, a vitamin B, dimethyl fumarate (DMF, also referred to as BG-12) and fingolimod (Gilenya).Type: ApplicationFiled: August 7, 2012Publication date: October 16, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Lawrence Steinman, Peggy Pui-Kay Ho
-
Publication number: 20140309193Abstract: There are provided inter alia compounds of formula (I) wherein R1, R2, R3, R4a and R4b are as defined in the specification and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.Type: ApplicationFiled: December 5, 2012Publication date: October 16, 2014Inventors: Peter William Andrew, Rana Lonnen, Mafalda Pires Damaso, Fritz-Frieder Frickel, Simon Christopher Hirst, Mark William Davies, Daniel Hamza
-
Patent number: 8859537Abstract: This invention relates to the use of a ligand of the 5-HT4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and/or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT4 receptor or of a functionally equivalent receptor.Type: GrantFiled: April 29, 2005Date of Patent: October 14, 2014Assignee: Centre National de la Recherche Scientifique-CNRSInventor: Valerie Compan
-
Patent number: 8859590Abstract: Inhibitors of BACE1 and compositions containing them are described. Use of the inhibitors and compositions containing them to treat Alzheimer's disease are described.Type: GrantFiled: December 4, 2009Date of Patent: October 14, 2014Assignee: Purdue Research FoundationInventor: Arun K. Ghosh
-
Publication number: 20140301958Abstract: The purpose of this patent is to teach the methods of application and compositions of cosmetic and therapeutic products for reducing wrinkle appearance and augmenting certain compartments of the facial integument of a mammal, especially a human. These methods and compositions utilize the hypodermis-targeted release from bioadhesive oral films, pastes or patches applied to oral mucosa or teeth for the purpose of improving the appearance or health of the lips and facial skin.Type: ApplicationFiled: April 20, 2012Publication date: October 9, 2014Inventors: Krzysztof Bojanowski, Hui Zhao
-
Publication number: 20140303229Abstract: Novel skin moisturizing compositions are applied onto dry skin, particularly mild to moderately dry skin, are non-irritating and contain at least one natural moisturizing factor, butyrospermum parkii, at least one silicone, and Panthenol.Type: ApplicationFiled: May 30, 2014Publication date: October 9, 2014Applicant: GALDERMA RESERCH & DEVELOPMENTInventor: Thierry RABOUILLE
-
Publication number: 20140302182Abstract: Embodiments of the invention generally relate to methods and supplements for increasing sex steroids and human growth hormone in a human being.Type: ApplicationFiled: June 10, 2014Publication date: October 9, 2014Inventors: Amy L. HEATON, Mitchell K. FRIEDLANDER, Dennis GAY
-
Publication number: 20140302150Abstract: The present invention relates to a pharmaceutical formulation, characterized by comprising a DPP-IV inhibitor and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.Type: ApplicationFiled: September 5, 2012Publication date: October 9, 2014Inventors: Umit Cifter, Ali Turkyilmaz, Gulay Yelken, Mehtap Saydam
-
Publication number: 20140302125Abstract: There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more calcium channel blocker, angiotensin II receptor blocker or angiotensin converting enzyme inhibitor along with one or more rate controlling excipient.Type: ApplicationFiled: August 23, 2012Publication date: October 9, 2014Applicant: Wockhardt Ltd.Inventors: Mandar Madhukar Kodgule, Premchand Dalichandji Nakhat, Amit Gupta, Girish Kumar Jain
-
Patent number: 8853256Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.Type: GrantFiled: May 31, 2007Date of Patent: October 7, 2014Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
-
Publication number: 20140296287Abstract: Disclosed herein are methods of treating a patient suffering from a cognitive disorder using compounds of Formulas 1 and 2 wherein the variables have the meaning disclosed in the specificationType: ApplicationFiled: March 18, 2014Publication date: October 2, 2014Applicant: Allergan, Inc.Inventors: John E. Donello, Fabien J. Schweighoffer, Lauren M. Luhrs
-
Publication number: 20140295002Abstract: Embodiments of the invention generally relate to methods and supplements for improving the health of human beings.Type: ApplicationFiled: June 10, 2014Publication date: October 2, 2014Inventors: Amy L. HEATON, Mitchell K. FRIEDLANDER, Dennis GAY
-
Publication number: 20140295003Abstract: A method of improving health in a canine includes administering to the canine a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland of the canines to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, and cysteine. When desired, the nutritional supplement may consist essentially of L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine, and schizonepeta powder.Type: ApplicationFiled: June 10, 2014Publication date: October 2, 2014Inventors: Amy L. Heaton, Mitchell K. Friedlander, Dennis Gay
-
Publication number: 20140294804Abstract: The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.Type: ApplicationFiled: April 7, 2014Publication date: October 2, 2014Applicant: SAINT LOUIS UNIVERSITYInventor: Daniela SALVEMINI
-
Patent number: 8846616Abstract: A method is presented for treating an inflammatory skin disorder in a human comprising: topically applying to the skin a composition comprising alpha-melanocyte stimulating hormone (?MSH) or an ?MSH analog in an amount effective to reduce skin inflammation in the human.Type: GrantFiled: November 9, 2010Date of Patent: September 30, 2014Assignees: Florida Agricultural and Mechanical University, The Board of Trustees at the University of ArkansasInventors: Mandip Singh Sachdeva, Cheryl Armstrong, Melissa A. Brown
-
Publication number: 20140288034Abstract: A compound having an ability to bind to an S1P receptor and represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like: wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.Type: ApplicationFiled: June 4, 2014Publication date: September 25, 2014Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shinji NAKADE, Hirotaka Mizuno, Takeji ONO, Masashi Minami, Hiroshi Saga, Hiroshi Hagiya, Takaki Komiya, Hiromu Habashita, Haruto Kurata, Kazuhiro Ohtsuki, Kensuke Kusumi
-
Publication number: 20140287040Abstract: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Applicant: Novartis AGInventors: Yatindra Joshi, James Kowalski, Jay Parthiban Lakshman, Alan Edward Royce, Wei-Qin Tong, Madhav Vasanthavada
-
Publication number: 20140288144Abstract: A compound of formula (I): R?āO-A-OāR??, in which R? and R? are a hydrogen atom or a monovalent radical of formula (IIa), or a monovalent radical of formula (IIb), it being understood that at least one of the radicals R? or R? is not a hydrogen atom and that, when none of the radicals R? and R? is a hydrogen atom, R? and R? are identical, and in which A is a divalent radical of formula (III): āCH(X1)-[C(X2)(X3)]p-CH(X4) in which X1, X2, X3 and X4 are identical or different and are either a hydrogen atom or a methyl radical or an ethyl radical, and p is an integer greater than or equal to 1 and less than or equal to 6. Also the method for preparing the compound of formula (I) and to the use thereof in cosmetics and as a drug.Type: ApplicationFiled: October 12, 2012Publication date: September 25, 2014Applicant: Societe D'Exploitation de Produits Pour Les Industries Chimiques SeppicInventors: Sandy Dumont, Jerome Guilbot, Stephanie Garcel, Laetitia Cattuzzato
-
Publication number: 20140288142Abstract: The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolisms dysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Inventors: Nicoletta ALMIRANTE, Stefano BIONDI, Ennio ONGINI, Laura STORONI, Alessia NICOTRA
-
Patent number: 8840923Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.Type: GrantFiled: December 23, 2008Date of Patent: September 23, 2014Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
-
Publication number: 20140275079Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, and R10 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Inventors: Lisa A. Hasvold, John Pratt, Keith F. McDaniel, George S. Sheppard, Dachun Liu, Steven W. Elmore, Robert D. Hubbard
-
Publication number: 20140275093Abstract: This invention provides compounds of formula (I): wherein ring A, X1, X2, X3, R2, R4b, R10, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.Type: ApplicationFiled: October 16, 2013Publication date: September 18, 2014Applicant: Millennium Pharmaceuticals, Inc.Inventors: Christopher Blackburn, Kenneth M. Gigstad, Sean J. Harrison, He Xu
-
Publication number: 20140274905Abstract: The present invention generally relates to methods of modulating Cav1.2 channels and Cav1.2 channel activators.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Duke UniversityInventors: Geoffrey S. Pitt, Adam S. Barnett, Xinhe Yin
-
Patent number: 8835480Abstract: The present invention relates to polyamides capable of inhibiting ARE-, GRE- and ERE-mediated gene regulation in cells. The invention also relates to methods to treat diseases related to ARE-, GRE- and ERE-mediated gene regulation.Type: GrantFiled: April 22, 2008Date of Patent: September 16, 2014Assignee: California Institute of TechnologyInventors: Peter B. Dervan, Nicholas G. Nickols
-
Publication number: 20140256702Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: March 4, 2014Publication date: September 11, 2014Applicant: THERAVANCE, INC.Inventors: Erik Fenster, Melissa Fleury, Adam D. Hughes
-
Publication number: 20140256783Abstract: The present invention relates to a substrate including a compound having blood anticoagulation activity and a hydrophilic polymer compound, wherein the amount of elution of the compound having blood anticoagulation activity is less than 0.6 ?g/ml, and a manufacturing method of a substrate, wherein after a compound having blood anticoagulation activity and a hydrophilic compound brought in contact with a substrate are irradiated with radiation, unreacted components are washed out.Type: ApplicationFiled: May 16, 2014Publication date: September 11, 2014Applicant: Toray Industries, Inc.Inventors: Hirokazu SAKAGUCHI, Hiroshi TAKAHASHI, Yoshiyuki UENO, Hiroyuki SUGAYA
-
Publication number: 20140249200Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on atorvastatin therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: ApplicationFiled: February 28, 2014Publication date: September 4, 2014Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITEDInventors: Rene Braeckman, William Stirtan, Paresh Soni
-
Publication number: 20140249192Abstract: The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula wherein R1 is selected from the group consisting of CO2R7 and CON(R7)SO2R7 wherein R1, R2, R3, R4, and R7 are as defined in the specification. The compounds may be administered to treat DP1, FP, EP1, EP3, TP and/or EP4 receptor mediated diseases or conditions.Type: ApplicationFiled: February 12, 2014Publication date: September 4, 2014Applicant: Allergan, Inc.Inventors: Jose L. Martos, William R. Carling, David F. Woodward, Jenny W. Wang, Jussi J. Kangasmetsa
-
Patent number: 8822496Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin and particular regimens for administering this combination. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.Type: GrantFiled: October 27, 2010Date of Patent: September 2, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Carla Haefner, Gerhard Steinmann, Jerry O. Stern, Chan-Loi Yong
-
Patent number: 8822463Abstract: A novel methylcyclohexane derivative, and a pharmaceutical composition including the same that is effective for the prevention or treatment of pain.Type: GrantFiled: September 28, 2011Date of Patent: September 2, 2014Assignee: Sk Biopharmaceuticals Co., Ltd.Inventors: Sung Jin Bae, Han Ju Yi, Sun Gwan Hwang, Mo Ses Jeong, Yeo Jin Yoon, Sang Mi Chae, Joo Young Park, Eun Ju Ryu
-
Patent number: 8822527Abstract: Disclosed herein are substituted biaryl alkyl amide compounds, methods of synthesizing substituted biaryl alkyl amide compounds and methods of treating diseases and/or conditions with substituted biaryl alkyl amide compounds.Type: GrantFiled: October 16, 2012Date of Patent: September 2, 2014Assignee: Biotheryx, Inc.Inventors: Kyle W. H. Chan, Frank Mercurio, David I. Stirling
-
Publication number: 20140243263Abstract: Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an incretin-like effect in the patient.Type: ApplicationFiled: April 2, 2014Publication date: August 28, 2014Inventor: Michael Rothkopf
-
Publication number: 20140243274Abstract: Compounds of formula R1-A-NHāCH(R2)āCOāR3 are presented. The compounds can be used to treat or alleviate conditions associated with bone loss or low bone density, or to inhibit osteoclast differentiation and stimulation, bone resorption and/or loosening of a prosthetic device. The compounds can be administered as a pharmaceutical composition or in a prosthetic device.Type: ApplicationFiled: April 21, 2014Publication date: August 28, 2014Applicant: Strongbone ABInventors: Anders GRUBB, Franciszek KASPRZYKOWSKI, Ulf LERNER, Beata ZOLNOWSKA, Regina KASPRZYKOWSKA
-
Publication number: 20140243373Abstract: There is described a group of novel cyclic amine derivative compounds having an EP4 receptor agonistic activity. Specifically, the compounds according to the invention are provided with analgesic, antinflammatory, antiglaucoma activity, and also with anti-osteoporosis and antiulcerative activity. The present invention therefore relates to novel cyclic amine derivative compounds, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as pain, glaucoma, ulcerative colitis and osteoporosis.Type: ApplicationFiled: July 4, 2011Publication date: August 28, 2014Applicant: Rottapharm S.P.A.Inventors: Manuela Borriello, Sabrina Pucci, Luigi Piero Stasi, Lucio Rovati
-
Publication number: 20140242201Abstract: Embodiments of the invention generally relate to supplements for increasing human growth hormone (hGH) levels in healthy human beings.Type: ApplicationFiled: May 6, 2014Publication date: August 28, 2014Applicant: Quality IP Holdings, Inc.Inventors: Amy L. HEATON, Mitchell K. FRIEDLANDER, Dennis GAY
-
Publication number: 20140235611Abstract: The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.Type: ApplicationFiled: September 27, 2012Publication date: August 21, 2014Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Atsushi Naganawa, Kensuke Kusumi, Kazuhiro Otsuki, Tetsuya Sekiguchi, Akito Kakuuchi, Koji Shinozaki, Hiroshi Yamamoto, Shigeyuki Nonaka
-
Publication number: 20140235564Abstract: A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NCCa-ATP channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.Type: ApplicationFiled: February 20, 2014Publication date: August 21, 2014Inventors: J. Marc Simard, Mingkui Chen
-
Publication number: 20140235576Abstract: The present invention relates to compounds of Formula (I), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are iGluR receptor inhibitors, and hence are useful in the treatment of psychiatric diseases or neurological disorders or a disease or disorder associated with abnormal activities of iGluR receptors.Type: ApplicationFiled: February 14, 2014Publication date: August 21, 2014Applicant: Kobenhavns UniversitetInventor: Lennart BUCH
-
Publication number: 20140235605Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.Type: ApplicationFiled: March 15, 2013Publication date: August 21, 2014Applicant: CELERA CORPORATIONInventor: CELERA CORPORATION
-
Patent number: 8809311Abstract: A process for improving the health of a subject, the process comprising orally administering a composition comprising hydroxytyrosol to the subject to provide the subject with a daily dose of about 0.1 to about 750 ?g hydroxytyrosol per kg of body weight, and a dietary supplement in dosage unit form for oral administration, the dosage unit form comprising a composition containing about 1 microgram to about 50 milligrams hydroxytyrosol or an ester or salt thereof.Type: GrantFiled: August 10, 2010Date of Patent: August 19, 2014Inventor: Darlene McCord
-
Publication number: 20140228321Abstract: The present invention provides compounds of Formula (I): (I), as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.Type: ApplicationFiled: September 24, 2012Publication date: August 14, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Jennifer X. Qiao, Heather Finlay, Ji Jiang, John Lloyd, Carol Hui Hu, Zulan Pi, George O. Tora, James Neels, Jon J. Hangeland, Todd J. Friends
-
Patent number: 8802142Abstract: The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation.Type: GrantFiled: July 24, 2006Date of Patent: August 12, 2014Assignee: UCB Pharma, S.A.Inventors: Michel Deleers, Jean-BenoƮt Hubert
-
Patent number: 8802718Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.Type: GrantFiled: September 5, 2012Date of Patent: August 12, 2014Assignee: Mochida Pharmaceuticals Co., Ltd.Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
-
Patent number: 8802659Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.Type: GrantFiled: August 5, 2010Date of Patent: August 12, 2014Assignee: Biogen Idec MA Inc.Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras